The (epi)genetics of human synovial sarcoma

D.R.H. de Bruijn, J.P.H. Nap, A.G. Kessel

Research output: Contribution to journalArticleAcademicpeer-review

35 Citations (Scopus)


Human synovial sarcomas are aggressive soft tissue tumors with relatively high rates of recurrences and metastases. They display a variable response to common treatment protocols such as radiation and chemotherapy. For the development of novel diagnostic, prognostic, and therapeutic approaches, detailed information on the molecular mechanisms underlying the development of these tumors is of imperative importance. Fusion of the SS18 and (one of the) SSX genes is a molecular hallmark of human synovial sarcomas. The SS18 and SSX genes encode nuclear proteins that exhibit opposite transcription regulatory activities, likely through epigenetic mechanisms. The SS18 protein functions as a transcriptional coactivator and interacts directly with members of the epigenetic chromatin remodeling and modification machineries. In contrast, the SSX proteins function as transcriptional corepressors and are associated with several Polycomb group proteins. Since the domains involved in these apparently opposite transcription regulatory activities are retained in the SS18-SSX fusion proteins, we hypothesize that these fusion proteins function as "activator-repressors" of transcription. The implications of this model for human synovial sarcoma development and future treatment are discussed.
Original languageEnglish
Pages (from-to)107-117
JournalGenes Chromosomes and Cancer
Issue number2
Publication statusPublished - 2007


  • polymerase-chain-reaction
  • ssx fusion transcripts
  • chromatin remodeling complexes
  • proto-oncoprotein syt
  • nuclear receptor coactivator
  • paraffin-embedded tissues
  • in-situ hybridization
  • leucine-zipper motif
  • high-dose ifosfamide
  • prognostic-factors


Dive into the research topics of 'The (epi)genetics of human synovial sarcoma'. Together they form a unique fingerprint.

Cite this